Pediatr Nephrol (2014) 29:415–422 DOI 10.1007/s00467-013-2642-1
ORIGINAL ARTICLE
Ceramides and cardiac function in children with chronic kidney disease Mark Mitsnefes & Philipp E. Scherer & Lisa Aronson Friedman & Ruth Gordillo & Susan Furth & Bradley A Warady & the CKiD study group
Received: 12 July 2013 / Revised: 12 September 2013 / Accepted: 16 September 2013 / Published online: 5 January 2014 # IPNA 2014
Abstract Background Chronic kidney disease (CKD) is associated with increased incidence of cardiac dysfunction. Recent animal studies have demonstrated that elevated levels of ceramides cause dilated lipotoxic cardiomyopathy. We hypothesized ceramides are increased in children with CKD and associated with abnormal cardiac structure and function. Methods Ceramide levels were determined in 93 children aged 1–16 years enrolled in the Chronic Kidney Disease in Children (CKiD) study and compared to levels from 24 healthy controls. Complete demographic, clinical, and laboratory information, and ceramide measurements were analyzed cross-sectionally. Echocardiography was performed to determine cardiac structure and function. Results Very long-chain C24:0 ceramides were the most abundant species in both control (56 %) and CKD subjects (55 %), followed by C24:1 (controls 19 %, CKD 23 %) and C22:0 (controls 19 %, CKD 13 %). Total serum ceramide levels were significantly higher in CKD children versus
M. Mitsnefes (*) Division of Nephrology and Hypertension, Cincinnati Children’s Hospital Medical Center, MLC: 7022, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA e-mail: [email protected] P. E. Scherer : R. Gordillo The University of Texas Southwestern Medical Center, Dallas, TX, USA L. A. Friedman Johns Hopkins University School of Public Health, Baltimore, MD, USA S. Furth University of Pennsylvania, Philadelphia, PA, USA B. A. Warady Children’s Mercy Hospital, Kansas City, MO, USA
controls (p
ORIGINAL ARTICLE
Ceramides and cardiac function in children with chronic kidney disease Mark Mitsnefes & Philipp E. Scherer & Lisa Aronson Friedman & Ruth Gordillo & Susan Furth & Bradley A Warady & the CKiD study group
Received: 12 July 2013 / Revised: 12 September 2013 / Accepted: 16 September 2013 / Published online: 5 January 2014 # IPNA 2014
Abstract Background Chronic kidney disease (CKD) is associated with increased incidence of cardiac dysfunction. Recent animal studies have demonstrated that elevated levels of ceramides cause dilated lipotoxic cardiomyopathy. We hypothesized ceramides are increased in children with CKD and associated with abnormal cardiac structure and function. Methods Ceramide levels were determined in 93 children aged 1–16 years enrolled in the Chronic Kidney Disease in Children (CKiD) study and compared to levels from 24 healthy controls. Complete demographic, clinical, and laboratory information, and ceramide measurements were analyzed cross-sectionally. Echocardiography was performed to determine cardiac structure and function. Results Very long-chain C24:0 ceramides were the most abundant species in both control (56 %) and CKD subjects (55 %), followed by C24:1 (controls 19 %, CKD 23 %) and C22:0 (controls 19 %, CKD 13 %). Total serum ceramide levels were significantly higher in CKD children versus
M. Mitsnefes (*) Division of Nephrology and Hypertension, Cincinnati Children’s Hospital Medical Center, MLC: 7022, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA e-mail: [email protected] P. E. Scherer : R. Gordillo The University of Texas Southwestern Medical Center, Dallas, TX, USA L. A. Friedman Johns Hopkins University School of Public Health, Baltimore, MD, USA S. Furth University of Pennsylvania, Philadelphia, PA, USA B. A. Warady Children’s Mercy Hospital, Kansas City, MO, USA
controls (p
